Statement Of Changes In Equity [Abstract]

Innate Pharma - Filing #2821023

Concept	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	—	156 476 EUR	63 984 EUR	—	3 950 EUR	—	372 131 EUR	355,000 EUR	—	155 976 EUR	—	20 759 EUR	369 617 EUR	217 416 EUR	134 912 EUR	—	3 941 EUR	—	—	—	472,000 EUR	—	3 197 EUR	299 932 EUR	137 961 EUR	167 119 EUR	3 049 EUR	1 099 EUR	121,000 EUR	299 932 EUR	167 240 EUR	1 099 EUR	3 049 EUR	3 197 EUR	137 840 EUR	121,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	63 984 EUR	—	—	63 984 EUR	—	—	—	—	—	—	—	—	—	—	—	20 759 EUR	—	—	—	20 759 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other comprehensive income	22,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	627,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive income	63 962 EUR	—	—	63 984 EUR	—	805,000 EUR	—	—	827,000 EUR	—	—	—	—	—	—	20 132 EUR	—	627,000 EUR	—	20 759 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Issue of equity	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	66 558 EUR	—	—	719,000 EUR	—	—	65 839 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	2 476 EUR	—	—	—	—	—	—	—	—	—	2 476 EUR	—	—	—	—	3 826 EUR	—	—	—	—	—	3 826 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—